EODData

MEMBERSHIP REGISTER LOG IN

OTCBB, VCNX: Vaccinex Inc

27 Mar 2026
LAST:

1.190

CHANGE:
 0.05		OPEN:
1.190		HIGH:
1.190		ASK:
0.000		VOLUME:
300
CHG(%):
4.41		PREV:
1.140		LOW:
1.190		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
27 Mar 261.1901.1901.1901.190300
26 Mar 261.1401.1401.1401.140300
25 Mar 261.0361.0501.0361.050500
20 Mar 261.2181.3130.5520.8882.1K
19 Mar 261.0001.2401.0001.2402.5K
18 Mar 261.0401.0401.0401.040300
17 Mar 261.0001.1800.9981.0904.9K
16 Mar 260.9880.9980.9880.9981.3K
13 Mar 260.5500.7000.3400.70012.2K

PROFILE

Name:Vaccinex Inc
About:Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate is pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 clinical for the treatment of Alzheimer's disease and has completed phase 2 study for the treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer; Pepinemab in combination with Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 clinical trial with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab and/or Ipilimumab which is in phase 2 clinical trial for melanoma; Pepinemab in combination with Trastuzumab and dendritic cell vaccines in phase 2 clinical trial for breast cancer. The company has also developed ActivMAb, a human antibody discovery platform based on a novel method for expressing and presenting complex multipass membrane proteins, as well as full-length human monoclonal antibodies on the surface of mammalian pox viruses. In addition, it develops CHS-114 and anti-CCR8 antibody; and VX5, which is in preclinical development to treat related to autoimmune disorders.It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; Emory University; Huntington Study Group; Catalent Pharma Solutions, LLC; and Surface Oncology, Inc. The company was incorporated in 2001 and is headquartered in Rochester, New York.
Sector:Healthcare
Industry:Biotechnology
Address:1895 Mount Hope Avenue, Rochester, NY, United States, 14620
Website:https://www.vaccinex.com
CUSIP:918640103
CIK:0001747866
ISIN:US9186401033
FIGI:BBG00469NFK4

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:1.108.0%
MA10:0.9919.7%
MA20:1.0117.4%
MA50:1.126.5%
MA100:0.8933.3%
MA200:0.8343.2%
STO9:80.00 
STO14:74.53
RSI14:52.97
WPR14:-9.30 
MTM14:0.19
ROC14:0.19 
ATR:0.32 
Week High:1.3110.3%
Week Low:0.55115.6%
Month High:1.3916.8%
Month Low:0.3443.2%
Year High:1.5026.1%
Year Low:0.25372.0%
Volatility:188.24